

Co-infection in COVID-19

# Co-infection in critically ill patients with COVID-19:

## An observational cohort study from England

Vadsala Baskaran<sup>1,2,3</sup>, Hannah Lawrence<sup>1,2,3</sup>, Louise Lansbury<sup>2</sup>, Karmel Webb<sup>2</sup>, Shahideh Safavi<sup>3,4</sup>, Izzah Zainuddin<sup>1</sup>, Tausif Huq<sup>1</sup>, Charlotte Eggleston<sup>1</sup>, Jayne Ellis<sup>5</sup>, Clare Thakker<sup>5</sup>, Bethan Charles<sup>6</sup>, Sara Boyd<sup>8,9</sup>, Tom Williams<sup>8</sup>, Claire Phillips<sup>10</sup>, Ethan Redmore<sup>10</sup>, Sarah Platt<sup>11</sup>, Eve Hamilton<sup>11</sup>, Andrew Barr<sup>11</sup>, Lucy Venyo<sup>11</sup>, Peter Wilson<sup>5</sup>, Tom Bewick<sup>12</sup>, Priya Daniel<sup>12</sup>, Paul Dark<sup>6,7</sup>, Adam R Jeans<sup>6</sup>, Jamie McCanny<sup>8</sup>, Jonathan D Edgeworth<sup>8</sup>, Martin J Llewelyn<sup>10</sup>, Matthias L Schmid<sup>11</sup>, Tricia M McKeever<sup>2,3</sup>, Martin Beed<sup>13,14</sup>, Wei Shen Lim<sup>1,3</sup>

**Running Title:** Co-infection in COVID-19

### Institutions:

<sup>1</sup> Department of Respiratory Medicine, Nottingham University Hospital NHS Trust, Nottingham NG5 1PB, UK

<sup>2</sup> Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Clinical Sciences Building, Nottingham City Hospital Campus, Hucknall Road, Nottingham NG5 1PB, UK

<sup>3</sup> NIHR Nottingham Biomedical Research Centre, Queen's Medical Centre, Nottingham NG7 2UH, UK

<sup>4</sup> Division of Respiratory Medicine, School of Medicine, University of Nottingham, Queens Medical Centre, Derby Rd, Lenton, Nottingham NG7 2UH, UK

<sup>5</sup> University College London Hospitals NHS Foundation Trust, 250 Euston Rd, London NW1 2PG, UK

<sup>6</sup> Salford Royal NHS Foundation Trust, Stott Ln, Salford M6 8HD, UK

<sup>7</sup> Division of Infection, Immunity and Respiratory Medicine, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester, M23 9PT

<sup>8</sup> Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, London SE1 9RT, UK

## Co-infection in COVID-19

<sup>9</sup>Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L69 3GE

<sup>10</sup>Brighton and Sussex University Hospitals NHS trust, Eastern Road, Brighton BN2 1ES, UK

<sup>11</sup>Newcastle Upon Tyne Hospitals NHS Foundation Trust, Freeman Rd, High Heaton, Newcastle upon Tyne NE7 7DN, UK

<sup>12</sup>University Hospitals of Derby and Burton NHS Foundation Trust, Uttoxeter Road, Derby DE22 3NE, UK

<sup>13</sup>Department of Critical Care, Nottingham University Hospital NHS Trust, Nottingham NG5 1PB, UK

<sup>14</sup>Division of Anaesthesia, School of Medicine, University of Nottingham, Queens Medical Centre, Derby Rd, Lenton, Nottingham NG7 2UH, UK

### **Corresponding author:**

Dr Vadsala Baskaran

Room B02, Clinical Sciences Building, Department of Respiratory Medicine

Nottingham City Hospital Campus, Nottingham University Hospitals NHS Trust

Hucknall Road, Nottingham NG5 1PB

Email: [vadsala.baskaran1@nottingham.ac.uk](mailto:vadsala.baskaran1@nottingham.ac.uk)

Tel: +44(0)115 9691169

**Word count:** 3072 words

**Keywords:** COVID-19, co-infection, ICU, antibiotic resistance

**Illustrations/ Tables:** 5

Co-infection in COVID-19

## Abstract

**Objective:** To describe the incidence and nature of co-infection in critically ill adults with COVID-19 infection in England.

**Methods:**

A retrospective cohort study of adults with COVID-19 admitted to seven intensive care units (ICUs) in England up to 18 May 2020, was performed. Patients with completed ICU stays were included. The proportion and type of organisms were determined at <48 and >48 hours following hospital admission, corresponding to community and hospital-acquired co-infections.

**Results:**

Of 254 patients studied (median age 59 years (IQR 49-69); 64.6% male), 139 clinically significant organisms were identified from 83(32.7%) patients. Bacterial co-infections were identified within 48 hours of admission in 14(5.5%) patients; the commonest pathogens were *Staphylococcus aureus* (four patients) and *Streptococcus pneumoniae* (two patients). The proportion of pathogens detected increased with duration of ICU stay, consisting largely of Gram-negative bacteria, particularly *Klebsiella pneumoniae* and *Escherichia coli*. The co-infection rate >48 hours after admission was 27/1000 person-days (95% CI 21.3-34.1). Patients with co-infections were more likely to die in ICU (crude OR 1.78, 95% CI 1.03-3.08,  $p=0.04$ ) compared to those without co-infections.

**Conclusion:**

We found limited evidence for community-acquired bacterial co-infection in hospitalised adults with COVID-19, but a high rate of Gram-negative infection acquired during ICU stay.

## Co-infection in COVID-19

### 1 Introduction

2 During previous viral pandemics, reported co-infection rates and implicated pathogens have  
3 varied. In the 1918 influenza pandemic an estimated 95% of severe illness and death was  
4 complicated by bacterial co-infection, predominantly *Streptococcus pneumoniae* and  
5 *Staphylococcus aureus* [1].

6  
7 As of 3 September 2020, over 25 million cases and 850 000 deaths due to COVID-19  
8 infection have been reported world-wide [2]. The symptoms associated with COVID-19  
9 infection are relatively non-specific. Fever and lower respiratory tract symptoms, such as a  
10 cough or breathlessness, are common in patients who require hospital care and radiological  
11 changes consistent with pneumonia are evident in up to 97% of these patients [3].  
12 Confirmation of acute COVID-19 infection is reliant on a positive SARS-CoV-2 polymerase  
13 chain reaction (PCR) test result. The immune response to SARS-CoV2 infection includes a  
14 rise in IL-6 and C-reactive protein (CRP), with higher levels associated with more severe  
15 disease [4, 5].

16  
17 The contribution of secondary or co-pathogens to COVID-19 infection is not well  
18 understood. The lack of an effective anti-viral agent against SARS-CoV2 combined with  
19 challenges in differentiating secondary bacterial co-infection from severe COVID-19  
20 infection alone, has fostered the widespread use of empirical antibiotics in the immediate  
21 management of patients hospitalised with COVID-19 infection. Over the spring wave of the  
22 pandemic, 83.1% of hospitalised patients in the UK received empirical antibiotic treatment  
23 [6].

24  
25 The utility of specific biomarkers such as procalcitonin to guide antibiotic therapy in severe  
26 respiratory tract infection, and specifically COVID-19 infection, is as yet uncertain [7, 8]. In  
27 the meantime, a better understanding of the incidence of co-infection in patients with  
28 COVID-19 infection and the pathogens involved is necessary for effective antimicrobial  
29 stewardship. The primary objective of this study was to determine the rate of laboratory-  
30 proven co-infection in critically ill adults with COVID-19 infection in England. Secondary aims

## Co-infection in COVID-19

31 were to describe the organisms, the characteristics of patients with co-infection and the  
32 antibiotic susceptibilities of identified bacteria.

## 33 **Methods**

### 34 **Data source**

35 A retrospective observational multicentre study of co-infection in adults with confirmed  
36 COVID-19 requiring intensive care unit (ICU) admission was performed. Seven acute  
37 hospitals from across England participated in the study including large (>1000 beds) tertiary  
38 hospitals and medium (500- 1000 beds) district hospitals: Nottingham University Hospitals  
39 NHS Trust, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Brighton and Sussex  
40 University Hospitals NHS Trust, Guy's and St Thomas' NHS Foundation Trust, Salford Royal  
41 NHS Foundation Trust, University Hospitals of Derby and Burton NHS Foundation Trust and  
42 University College London Hospitals NHS Foundation Trust.

43

### 44 **Study population**

45 Case inclusion criteria were adults aged >16 years with completed ICU admissions  
46 (discharged from or died whilst in ICU) for COVID-19 pneumonia (i.e. requiring Level 2 or  
47 Level 3 care according to the classification by the Intensive Care Society, UK) from disease  
48 emergence to 18 May 2020. SARS-CoV-2 was confirmed using reverse transcriptase-  
49 polymerase chain reaction (RT-PCR) from a respiratory specimen. Participating sites were  
50 asked to enter data for either: 1) all identified patients, or 2) a random selection of at least  
51 ten patients from across their eligible cohort. Where more than one critical care area  
52 existed at a participating site, a random selection from across areas was requested to avoid  
53 selection bias. Exclusion criteria were defined as: COVID-19 infection diagnosed >48 hours  
54 after hospital admission or a hospital admission in the last 14 days (hospital-acquired  
55 COVID-19) and patients transferred into ICU from a different hospital. Only the first  
56 admission to ICU was included.

57

### 58 **Data collection**

59 Personal information was removed at the point of participating site data entry onto a secure  
60 online database platform (REDCap Cloud). Data were gathered from electronic medical

## Co-infection in COVID-19

61 records. Fields collected were: demographics (age, gender, ethnicity, presence or absence of  
62 co-morbidity as defined in the Intensive Care National Audit & Research Centre (ICNARC)  
63 report on COVID-19 in critical care (Online Resource 1) and type 2 diabetes mellitus);  
64 hospital admission details (date, days of symptom onset prior to admission and radiology  
65 findings); ICU details (date of admission, mechanical ventilation during the first 24 hours,  
66 advanced respiratory support (Online Resource 1), acute physiology and chronic health  
67 evaluation (APACHE II) score and outcomes); antibiotics received and all microbiology test  
68 results to the end of the ICU admission (including any identified antimicrobial resistance).

69

### 70 **Definitions**

71 Diagnostic microbiology tests were performed as per standard testing protocols within NHS  
72 laboratories at individual participating sites. Microbiology results included in the analysis  
73 were: standard culture (blood, sputum, tracheal-aspirate, bronchoalveolar lavage (BAL),  
74 urine) and validated culture-independent tests such as respiratory viral PCR (see Online  
75 Resource 2), urinary antigens and serology for *Mycoplasma pneumoniae* (IgM/ IgG). Co-  
76 infection was defined as present if a likely pathogen was identified in a clinical sample taken  
77 for diagnostic purposes. Culture results were excluded if they were considered to represent  
78 contamination or colonisation. Specifically, this applied to the following situations: blood  
79 cultures yielding common skin contaminants in a single sample (Coagulase-negative  
80 Staphylococci, *Micrococcus spp.*, viridans group streptococci, *Propionibacterium spp.*,  
81 *Corynebacterium spp.*, *Bacillus spp.*) without a concurrent positive culture from an  
82 indwelling line tip [9-11], *Candida spp.* cultured from respiratory and urinary catheter  
83 samples [12, 13], respiratory samples yielding Gram-positive organisms typically present in  
84 the oropharyngeal flora [14], growth of *Enterococcus spp.* in a single catheter urinary  
85 specimen [15]. Radiology findings were defined based on the COVID-19 British Society of  
86 Thoracic Imaging reporting template [16]. Where both chest CT and CXR findings were  
87 available, chest CT findings were prioritised.

88

### 89 **Statistical analysis**

90 Demographics, clinical and disease characteristics were described using appropriate  
91 descriptive statistics for: i) those with co-infection, and ii) those without co-infection.

## Co-infection in COVID-19

92 Characteristics of patients in the study were also compared with the patients in the  
93 Intensive Care National Audit & Research Centre (ICNARC) report on COVID-19 in critical  
94 care, 22 May 2020. The proportion of co-infection (%) was determined at three time points:  
95 on admission, within 48 hours, and during ICU admission (from day of ICU admission to ICU  
96 discharge or death in ICU). The co-infection rate was calculated per 1000 person-days based  
97 on the first co-infection detected in hospital per patient (person-time was determined from  
98 date of hospital admission to date of first co-infection, date of discharge from ICU or date of  
99 death in ICU, whichever came first for each patient). Univariate logistic regression analyses  
100 were conducted to determine the association between selected variables (age, gender,  
101 study site, ethnicity and co-morbidities) and the odds of a) developing co-infection during  
102 admission, and b) co-infection and mortality in ICU. Competing-risks regression analysis was  
103 conducted to assess if patients with co-infection had a longer length of hospital stay (from  
104 hospital admission to the end of ICU admission) than those without co-infection, with death  
105 as a competing-event. Co-pathogens were described separately for bacterial, viral and  
106 fungal infections. The proportion of bacterial co-pathogens with antimicrobial resistance  
107 was recorded.

108

109 An analysis of type of pathogens identified at different time points from admission was  
110 performed ( $\leq 48$  hours and  $>48$  hours following admission) to identify those with community  
111 vs hospital-acquired co-infection. Pathogens identified within 48 hours of hospital admission  
112 were listed by type of test performed. A sub-analysis of the hospital-acquired co-infection  
113 was performed to identify the type of pathogens detected early (3-7 days into hospital  
114 admission) and late ( $>7$  days into hospital admission). Statistical analyses were performed  
115 using Stata MP/15.1.

116

117


## Co-infection in COVID-19

### 118 Results

119 Of 599 eligible patients during the study period, 254 patients with completed ICU episodes  
120 were studied (**Fig 1**).

121

122 **Fig 1:** Flowchart of study population



123

124

125 <sup>a</sup> See Online Resource 3 for exact breakdown

126

127 The median age of the study cohort was 59 years (IQR 49-69, range 19-84) and 164 (64.6%)  
128 patients were male; similar to corresponding data from the ICNARC cohort (

## Co-infection in COVID-19

129 **Table 1)**[17]. Patients were admitted to hospital between 21 Feb 2020 and 1 May 2020. The  
130 median time from onset of symptoms to admission was seven days (IQR 5-10). The median  
131 time from hospital admission to ICU admission was one day (IQR 0-2). Antibiotics were  
132 prescribed to 35 (13.8%) patients before hospital admission and to 228 (89.8%) patients  
133 within 48 hours of admission. Throughout the course of admission, 241 (94.9%) of patients  
134 received antibiotics at some point.

135

Co-infection in COVID-19

136 **Table 1:** Characteristics of study population in comparison with ICNARC data

	Without coinfection n (%)	With coinfection n (%)	ICNARC data <sup>a</sup> n (%)
<b>Number of patients</b>	171 (67.3)	83 (32.7)	9026
<b>Age</b>			*
18-49	47 (27.5)	17 (20.5)	
50-64	51 (29.8)	42 (50.6)	
65-74	47 (27.5)	19 (22.9)	
75-84	26 (15.2)	5 (6.0)	
<b>Gender</b>			[N=9022]
Male	106 (62.0)	58 (69.9)	6403 (71.0)
Female	65 (38.0)	25 (30.1)	2619 (29.0)
<b>Ethnicity</b>			[N=8185]
White	108 (63.2)	44 (53.0)	5468 (66.8)
Black	13 (7.6)	10 (12.1)	1245 (15.2)
Asian	16 (9.4)	5 (6.0)	797 (9.7)
Mixed	3 (1.8)	2 (2.4)	138 (1.7)
Other	4 (2.3)	3 (3.6)	537 (6.6)
<sup>§</sup> BAME	36 (21.1)	20 (24.1)	-
Unknown	27 (15.8)	19 (22.9)	-
<b>Co-morbidities</b>			[N=8777]
Cardiovascular	3 (1.8)	0 (0.0)	42 (0.5)
Respiratory	0 (0.0)	2 (2.4)	74 (0.8)
Renal	3 (1.8)	2 (2.4)	144 (1.6)
Liver	0 (0.0)	0 (0.0)	33 (0.4)
Metastatic disease	0 (0.0)	0 (0.0)	38 (0.4)
Haematological malignancy	6 (3.5)	1 (1.2)	144 (1.6)
Immunocompromised	11 (6.5)	2 (2.4)	295 (3.4)
Type 2 diabetes mellitus	47 (27.5)	19 (22.9)	N/A
<b>Indicator of acute severity</b>			
Mechanically ventilated within first 24h			5298 (62.8) <sup>b</sup>
APACHE II Score, mean (SD)	13.3 (5.6)	14.2 (5.5)	14.7 (5.3) <sup>c</sup>
PaO <sub>2</sub> /FiO <sub>2</sub> ratio (kPa), median (IQR); [mmHg]	17.2 (12.6-22.3); [129 (95-168)]	17.4 (11.8-23.7); [131 (88.5-178.1)]	15.8 (11.3-22.0) <sup>d</sup>
≤ 13.3 kPa (< 100 mmHg)	49 (28.7)	24 (28.9)	2982 (36.8)
> 13.3 and ≤ 26.7kPa (100 - 200 mmHg)	92 (53.8)	41 (49.4)	3961 (48.9)
> 26.7 kPa (> 200 mmHg)	30 (17.5)	18 (21.7)	1161 (14.3)
<b>LOS from hospital admission to the end of ICU admission (days), median (IQR)</b>			
Survivors	9 (4-14)	22 (17-27)	N/A
Non-survivors	7 (4-12)	17 (11-20)	

137 <sup>a</sup> Intensive Care National Audit & Research Centre (ICNARC) report from 22 May 2020

138 \* Median age= 60 (51-68)

139 Denominators: <sup>b</sup> N=8433, <sup>c</sup> N=8648 and <sup>d</sup> N=8104

## Co-infection in COVID-19

140 The overall median length of stay (LOS) in ICU was nine days (IQR 4-17); 10 days (IQR 4-18)  
141 for survivors and nine days (IQR 5-15) for non-survivors. One hundred and fifty-one patients  
142 (59.5%) were mechanically ventilated within 24 hours of admission, and 158 patients  
143 (62.2%) received advanced respiratory support (invasive ventilation, CPAP via trans-  
144 laryngeal tube, extracorporeal respiratory support) during admission. Of those who were  
145 discharged from ICU (n=172 patients), two patients (1.2%) died in hospital, 147 patients  
146 (85.5%) were discharged from hospital and 23 patients (13.4%) remained in hospital at the  
147 end of the study.

148  
149 All patients had either a CXR (n=246 patients) and/or a chest CT scan (n= 74 patients).  
150 Classic/ probable COVID-19 radiographic changes were recorded in 209 patients (82.3%),  
151 five (2%) had normal imaging, 27 (10.6%) had indeterminate changes and 13 (5.1%) had  
152 non-COVID19 findings.

153  
154 In total, co-infection was identified in 83 (32.7%) patients from hospital admission to the  
155 end of ICU stay; median time to co-infection was 9 days (IQR 6-14). The list of identified  
156 pathogens and contaminants from standard cultures (blood, BAL, sputum and tracheal  
157 aspirate) is available in Online Resource 4. On the day of admission, co-pathogens were  
158 identified in four patients (1.6%), rising to 14 (5.5%) patients within the first 48 hours of  
159 hospital admission. Fifteen pathogens were identified from 14 patients within 48 hours; 14  
160 bacterial and one viral pathogen (**Table 2**). None of these pathogens were identified from  
161 blood culture. In a sensitivity analysis excluding the hospital which contributed a third of  
162 cases, the 48-hour co-infection rate remained similar (Online Resource 5). The commonest  
163 co-pathogen within 48 hours of hospital admission was *S. aureus*, three methicillin-  
164 susceptible (MSSA) and one methicillin-resistant *S. aureus* (MRSA) (4 patients). Two positive  
165 Mycoplasma IgG/ IgM tests in separate patients were deemed false positives and excluded  
166 from the analysis. The number of tests performed within 48 hours of hospital admission are  
167 listed in Online Resource 6, by type of tests and study site. For bacterial co-pathogens, the  
168 antimicrobial susceptibilities are described in Online Resource 7.

169

Co-infection in COVID-19

170 **Table 2:** Organisms identified within 48 hours of hospital admission

Type of test	Pathogens	No of pathogens
<b>Tracheal aspirate or sputum culture</b>		
	<i>Escherichia coli</i>	1
	<sup>a</sup> <i>Pseudomonas sp</i>	1
	<i>Pseudomonas aeruginosa</i>	1
	<i>Enterobacter cloacae complex (AmpC)</i>	1
	<sup>a</sup> <i>Staphylococcus aureus</i> (MSSA)	2
<b>BAL PCR/ culture</b>		
	<sup>b</sup> <i>Staphylococcus aureus</i> (MSSA & MRSA)	2
	<i>Klebsiella pneumoniae</i>	1
<b>Other tests</b>		
Pneumococcal urinary antigen test	<sup>a</sup> <i>Streptococcus pneumoniae</i>	2
MSU	<i>Escherichia coli</i>	2
Respiratory viral PCR	<i>Mycoplasma pneumoniae</i>	1
	<sup>a</sup> <i>Metapneumovirus</i>	1

171 <sup>a</sup> Pathogens identified on the day of admission (one out of two *Staphylococcus aureus* was from tracheal  
 172 aspirate or sputum culture and one out of two pneumococcal urinary antigen tests was positive on the day of  
 173 admission), total= 4


174 <sup>b</sup> One out of two organisms was Methicillin-resistant *Staphylococcus aureus* (MRSA). The same patient also had  
 175 MRSA in pleural fluid culture after 48 hours into hospital admission.

176  
 177

## Co-infection in COVID-19

178 Beyond 48 hours of hospital admission to the end of ICU stay, 124 co-pathogens were  
179 identified in 77 (30.3%) patients; 29 pathogens from Days 3 – 7 and 95 pathogens from Day  
180 8 onwards (**Fig 2**). All were bacterial pathogens (n=122) except for two fungal organisms.  
181 The commonest co-pathogens identified were Gram-negative bacteria, including *Klebsiella*  
182 *spp.* (23 patients) and *Escherichia coli* (20 patients). No viral co-pathogens were detected. Of  
183 the two fungal co-pathogens, one was *Aspergillus fumigatus* from a tracheal aspirate culture  
184 obtained on Day 5 in a 54-year old male. The other was *Candida parapsilosis* from a blood  
185 culture taken at Day 7 in a 55-year old lady. Neither patient had any pre-existing co-  
186 morbidities.  
187

188 **Fig 2:** Bacterial pathogens detected after 48 hours of hospital admission; 124 pathogens  
189 detected



190  
191

192 Reported as proportion (%) of the total number of bacterial pathogens detected within '3-7 days' and '>7 days'  
193 from hospital admission.  
194

## Co-infection in COVID-19

195 On univariate analyses, patients aged 50-64 years were more likely to have a co-infection  
196 than those aged 18-49 years. No other significant association was found (

## Co-infection in COVID-19

197 **Table 3**). Patients with co-infections were more likely to die in ICU (n=34, crude OR 1.78,  
198 95% CI 1.03-3.08, p=0.04) and had a longer hospital LOS (measured from admission to  
199 hospital to the end of ICU admission, subhazard ratio= 0.53, 95% CI 0.39-0.71, p< 0.001)  
200 compared to those without co-infections (n=48 died).

201

202

Co-infection in COVID-19

203 **Table 3:** Univariate logistic regression analyses investigating the association between  
 204 variables of interest and odds of developing co-infection.

	<b>Crude OR (95% CI)</b>	<b>p value</b>
<b>Number of patients</b>		
<b>Age</b>		
18-49	1 (Reference)	
50-64	2.28 (1.14-4.53)	0.019*
65-74	1.12 (0.52-2.41)	0.777
75-84	0.53 (0.18-1.61)	0.263
<b>Gender</b>		
Male	1 (Reference)	
Female	0.70 (0.40-1.23)	0.218
<b>Ethnicity</b>		
White	1 (Reference)	
Black	1.89 (0.77-4.62)	0.164
Asian	0.77 (0.26-2.22)	0.625
Mixed	1.64 (0.26-10.13)	0.597
Other	1.84 (0.40-8.57)	0.437
<sup>a</sup> BAME	1.36 (0.71-2.61)	0.349
Unknown	1.73 (0.87-3.42)	0.117
<b>Co-morbidities</b>		
Cardiovascular	-	
Respiratory	-	
Renal	1.38 (0.23-8.43)	0.725
Liver	-	
Metastatic disease	-	
Haematological malignancy	0.34 (0.04-2.83)	0.316
Immunocompromise	0.36 (0.08-1.65)	0.187
Type 2 diabetes mellitus	0.78 (0.42-1.44)	0.434

205 \*p value of <0.05 denotes a significant difference # median and IQR

206 <sup>a</sup>BAME is the total of Black, Asian, Mixed and Other ethnicities

207

Co-infection in COVID-19

## 208 Discussion

### 209 Principal findings

210 Bacterial co-infection within 48 hours of hospital admission for COVID-19 infection in adults  
211 was uncommon; 1.6% on admission and 5.5% within 48 hours. The commonest pathogens  
212 identified within the first 48 hours of hospital admission were *Staphylococcus aureus* and  
213 *Streptococcus pneumoniae*. The proportion of pathogens detected increased with duration  
214 of ICU stay and consisted largely of Gram-negative bacteria, particularly *Klebsiella*  
215 *pneumoniae* and *Escherichia coli*. The co-infection rate >48 hours after admission was 27.0  
216 per 1000 person-days (95% CI 21.3-34.1).

217

### 218 Comparison with literature:

219 Concern regarding co-infection during viral pandemics, specifically respiratory co-infection  
220 with a bacterial pathogen, is borne from previous experience in influenza. During the 2009  
221 H1N1 influenza A pandemic, early co-infection rates were high; 22.5% within 72 hours of  
222 admission in adults requiring critical care [18]. In contrast, limited evidence from studies of  
223 Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome suggest lower  
224 co-infection rates (10.3 to 18.5%) [19, 20]. In COVID-19, systematic reviews based on studies  
225 predominantly from China reported low estimates (<7%) of bacterial co-infection [21-23]. In  
226 the UK, retrospective single-centre studies have observed low rates of bacterial co-infection  
227 [24-26]. Hughes *et al.* detected early bacterial infection (0-5 days from admission) in 3.2% of  
228 all hospitalised patients (13.5% of those requiring critical care), increasing to 6.1%  
229 throughout admission [25]. Youngs *et al.* reported bacterial co-infection within 48 hours of  
230 admission to ICU in 8% of patients with COVID-19 compared to 58% of patients with  
231 influenza, with no difference in the incidence of late infection between the two groups [26].  
232 In the US, higher early bacterial co-infection rates (16.6%) were identified by Crotty *et al.*;  
233 respiratory cultures positive for oral bacteria flora constituted 15/25 of these cases [27]. In  
234 contrast to studies that relied on predominantly culture-based techniques, Kreitmann *et al.*  
235 identified early bacterial co-infection in 27.7% (13/47) of their prospective cohort of  
236 ventilated patients using a multiplex PCR assay with only one case identified by  
237 conventional culture [28]. In France, a single centre study using three multiplex PCR assays

## Co-infection in COVID-19

238 performed on respiratory specimens or nasopharyngeal swabs in addition to standard  
239 culture techniques retrospectively identified bacterial co-infection in 28% of 92 ICU  
240 admissions [29]. Variations in case definitions, diagnostic testing and geography may partly  
241 account for the differences observed between studies although overall, there is a  
242 suggestion that increased severity of disease, particularly when ICU care is required, is  
243 associated with increased rates of co-infection.

244

245 The prevalence of nosocomial infection is 20.6% and increases with duration of ICU stay [30,  
246 31]. The rate of ventilator-acquired pneumonia is estimated at 1.2-8.5 per 1000 ventilator  
247 days and occurs in 9-27% of ventilated patients [32]. Our observed co-infection rate is  
248 relatively high, consistent with a patient cohort with long ICU stays (median 10 days) and  
249 requiring high levels of respiratory support.

250

251 Consistent with reports from other studies, the commonest co-infecting bacteria identified  
252 within 48 hours of admission was *S. aureus* [25, 28, 33]. In patients in whom early co-  
253 infection is suspected clinically, due consideration of *S. aureus* is warranted. However, the  
254 rate of *S. aureus* co-infection is markedly lower than that observed in pandemic influenza,  
255 suggesting it is a less significant issue with COVID-19 infection [18]. The predominant late  
256 pathogens observed were Gram-negative bacteria, particularly *K. pneumoniae*. These  
257 pathogens are commonly associated with hospital and ventilator-acquired pneumonia and  
258 have been reported as common co-pathogens in COVID-19 infections, particularly ICU  
259 cohorts [21, 22, 34-36]. The predominance of Gram-negative bacteria in these studies likely  
260 reflects nosocomial infection following prolonged ICU stay and empirical antibiotic use.

261

262 Viral co-pathogen was identified in one patient in our cohort; lower than the 3% (95% CI 1-  
263 6%) viral co-infection rate reported in systematic reviews and in contrast to the 20.7% viral  
264 co-detection rate reported by Kim *et al.* in Northern California [21, 37]. The 2019/20  
265 influenza season in the UK ended in late March [38]. Other UK cohorts recruited during the  
266 spring wave of COVID-19 (March - May 2020) similarly reported very little or no viral co-  
267 infection [25, 36].

268

## Co-infection in COVID-19

### 269 **Strengths and limitations**

270 This pragmatic multicentre study provides novel data on both community-acquired and  
271 nosocomial co-infection in patients with COVID-19 requiring ICU care in England. The ICU  
272 cohort represents those with severe disease who were subject to more rigorous  
273 microbiology sampling. A key limitation of the study is its retrospective observational design  
274 subject specifically to case selection, ascertainment and sampling biases. Inclusion of  
275 consecutive eligible patients was not feasible due to pandemic workload constraints. To  
276 minimise case selection bias, participating sites submitted a random sample of their eligible  
277 cohort, although random sampling methods were not standardised. The impact of  
278 ascertainment bias due to differences in the proportion of eligible cases submitted by each  
279 institution was reduced through the participation of multiple centres. The study cohort was  
280 comparable to the ICNARC cohort except for an under-representation of patients of Black,  
281 Asian and Minority Ethnicity (BAME). Our results may not be applicable to settings with  
282 larger BAME populations. Restriction of our cohort to those with completed ICU admissions  
283 excluded: i) frailer patients in whom ICU care was deemed not appropriate, and ii) patients  
284 with very long ICU stays. Co-infection, particularly nosocomial infection, may be higher in  
285 these patients.

286

287 A second key limitation is that although results likely to represent contamination were  
288 excluded, some pathogens found in respiratory tract samples may represent colonisation  
289 rather than active co-infection. However, as sputum samples sent from ICU reflect clinical  
290 concern of lower respiratory tract infection (especially during the pandemic timeframe) and  
291 positive culture represents predominant presence of a pathogen rather than as part of  
292 mixed flora, we have taken these results to represent infection. If colonising pathogens  
293 were wrongly attributed as causing infection, the direction of bias would be towards falsely  
294 higher co-infection rates observed in our study.

295

296 Thirdly, reliance on culture dependent techniques may have falsely decreased co-infection  
297 rates. Antibiotic use prior to admission was low (13.8%), increasing the reliability of culture-  
298 based methods on admission. However, detection of pathogens later into admission would  
299 have been influenced by sampling bias and the use of empirical antibiotics. Fourthly,  
300 although seven hospitals participated in this study, one study site contributed a third of

## Co-infection in COVID-19

301 cases; observed 48-hour co-infection rate excluding this site was, however, similar to overall  
302 results.

303

### 304 **Implications for future work**

305 Notwithstanding these limitations, our data indicate that early in hospitalisation, bacterial  
306 co-infection in COVID-19 is very uncommon and support the recommendations that  
307 empirical antibiotics should not be started routinely in primary care or at the point of  
308 hospital admission without clinical suspicion of bacterial infection [8]. The high rate of co-  
309 infection found late in illness among patients requiring ICU and involving nosocomial  
310 pathogens is concerning. It is plausible that reducing unnecessary early antibiotic exposure  
311 in patients with COVID-19 could reduce their risk of late, Gram negative, potentially  
312 antibiotic resistant infections [39, 40].

313

314 Since study completion, dexamethasone has been shown to decrease mortality in patients  
315 hospitalised with COVID-19 who require oxygen support or invasive mechanical ventilation  
316 [41]. Consequently, dexamethasone has become established as standard of care for these  
317 patients in many countries. This may increase the already high rate of bacterial co-infection  
318 we observed in ICU-treated patients. A high level of microbiological vigilance is  
319 recommended as part of the management of these patients. In the setting of seasonal  
320 changes in respiratory pathogens, ongoing surveillance for co-infections in patients  
321 hospitalised with COVID-19, ideally through prospective studies with standardised sampling  
322 protocols, is advised.

323

Co-infection in COVID-19

## 324 **Declarations**

### 325 **Funding**

326 This research was funded by the NIHR Nottingham Biomedical Research Centre. The views  
327 expressed are those of the author(s). The funders had no role in the design, analysis or write  
328 up of this manuscript. Grant number: BRC-1215-20003.

329

### 330 **Conflicts of interest/ Competing interests**

331 Professor Lim reports grants from National Institute for Health Research (NIHR), grants from  
332 Pfizer, outside the submitted work. Paul Dark is funded by NIHR Manchester BRC as sub-  
333 theme lead in Respiratory Infections.

334

### 335 **Availability of data and material**

336 Data are available from the corresponding author on reasonable request.

337

### 338 **Ethical approval**

339 Ethical approval was given by HRA and REC; protocol number:20RM040, IRAS project  
340 ID:284341. Section 251 support from the Confidentiality Advisory Committee for use of  
341 anonymised NHS patient data was not required according to the temporary General Notice  
342 issued for COVID-19 purposes by the Secretary of State for Health and Social Care under the  
343 Health Service Control of Patient Information Regulations 2002.

### 344 **Authors' contributions**

345 All included authors fulfil the criteria of authorship; VB and HL are joint first authors for this  
346 manuscript. WSL, VB and HL had substantial contributions to the study conception and  
347 design. All authors had substantial contributions to the data acquisition. VB performed the  
348 analyses. All authors had substantial contributions to the results interpretation. VB and HL  
349 wrote the original draft. All authors revised the manuscript critically for important  
350 intellectual content, provided the final approval of the version to be published and agreed  
351 to be accountable for all aspects of the work in ensuring that questions related to the  
352 accuracy or integrity of any part of the work are appropriately investigated and resolved.

## Co-infection in COVID-19

353 **Acknowledgement:**

354 We wish to thank Mr Glenn Hearson for building the study database on the secure online  
355 database platform (REDCAP Cloud).

356

Co-infection in COVID-19

## 357 **Supplementary Files**

### 358 **Online Resource 1**

359 **Definition (based on ICNARC report on COVID-19 in critical care)**<sup>9</sup>

360 **Comorbidities** must have been evident within the six months prior to critical care and  
361 documented at or prior to critical care:

- 362 • Cardiovascular: symptoms at rest
- 363 • Respiratory: shortness of breath with light activity or home ventilation
- 364 • Renal: renal replacement therapy for end-stage renal disease
- 365 • Liver: biopsy-proven cirrhosis, portal hypertension or hepatic encephalopathy
- 366 • Metastatic disease: distant metastases
- 367 • Haematological malignancy: acute or chronic leukaemia, multiple myeloma or  
368 lymphoma
- 369 • Immunocompromise: chemotherapy, radiotherapy or daily high dose steroid  
370 treatment in previous six months, HIV/AIDS or congenital immune deficiency
- 371 • Type II diabetes mellitus

372

373 **Mechanical ventilation during the first 24 hours** was identified by the recording of a  
374 ventilated respiratory rate, indicating that all or some of the breaths or a portion of the  
375 breaths (pressure support) were delivered by a mechanical device. This usually indicates  
376 invasive ventilation; BPAP (bi-level positive airway pressure) would meet this definition but  
377 CPAP (continuous positive airway pressure) does not.

378

379 **Advanced respiratory support** was defined as invasive ventilation, BPAP via trans-laryngeal  
380 tube or tracheostomy, CPAP via trans-laryngeal tube, extracorporeal respiratory support.

381

382

383

384

**Online Resource 2**

Study site	Viral testing panel
Nottingham University Hospitals	Influenza A & B, RSV, Rhinovirus, Enterovirus, Adenovirus, Parechovirus, Parainfluenza pool (types 1-4), Human metapneumovirus, Bocavirus
Newcastle Upon Tyne Hospitals	Influenza A & B, Respiratory syncytial virus (RSV), Rhinovirus, Human metapneumovirus, Adenovirus, Parainfluenza pool (types 1-4)
Brighton and Sussex University Hospitals Guy's & St Thomas'	Influenza A & B, RSV Influenza A & B, RSV, Enterovirus, Rhinovirus, Parainfluenza, Adenovirus, Human metapneumovirus
Salford Royal	Influenza A & B, RSV
University Hospitals of Derby & Burton	Influenza A & B, RSV, Parainfluenza, Rhinovirus, Human metapneumovirus, Adenovirus
University College London	Influenza A & B, RSV, Parainfluenza pool (types 1-4), Human metapneumovirus, Adenovirus, Rhinovirus

**Online Resource 3**

Study site	Met inclusion criteria <sup>a</sup>	Still in ICU <sup>b</sup>	Transfers from other hospital/ Hospital-acquired COVID-19 <sup>c</sup>	Eligible <sup>d</sup>	Entered into database (% of those eligible)
Nottingham University Hospitals	97	11	1	85	79 (92.9)
Newcastle Upon Tyne Hospitals	100	4	20	76	48 (63.2)
Brighton and Sussex University Hospitals	58	8	4	46	45 (64.3)
Guy's & St Thomas' NHS Foundation Trust	316	0	103	213	34 (16.0)
Salford Royal	46	3	11	32	22 (68.8)
University Hospitals of Derby & Burton	54	1	0	53	16 (30.2)
University College Hospitals London	138	32	32	74	10 (13.5)
<b>Total</b>	<b>809</b>	<b>59</b>	<b>171</b>	<b>579</b>	<b>254 (43.9)</b>

d= a- (b+c)

Co-infection in COVID-19

**Online Resource 4**

Table S 1: Results and classification as likely pathogen or contaminant among positive cultures taken from patients

<b>Blood culture</b>					
<b>Likely pathogen</b>	<b>n</b>	<b>N</b>	<b>Likely contaminant</b>	<b>n</b>	<b>N</b>
Coagulase negative Staphylococcus	13	6	Coagulase negative Staphylococcus	47	36
<i>Enterococcus spp.</i>	8	5	<i>Propionibacterium sp.</i>	2	2
<i>Klebsiella spp.</i>	3	2	<i>Streptococcus oralis</i>	1	1
<i>Citrobacter koseri</i>	3	2	<i>Micrococcus luteus</i>	1	1
Candida parapsilosis	1	1	<i>Diphtheroid bacilli</i>	1	1
<i>Escherichia coli</i>	1	1	<i>Anaerobic streptococci</i>	1	1
<i>Pseudomonas spp.</i>	1	1	<i>Streptococcus species (Facklamia Languida)</i>	1	1
<i>Staphylococcus aureus</i>	1	1	<i>Streptococcus parasanguinis</i>	1	1
<i>Haemophilus influenzae</i>	1	1	<i>Granulicatella adiacens</i>	1	1
	<u>32</u>	<u>20</u>	<i>Saccharomyces cerevisiae</i>	1	1
			<i>Actinomyces sp.</i>	1	1
			<i>Corynebacterium striatum</i>	1	1
			<i>Lysinbacillus sphaericus</i>	1	1
				<u>60</u>	<u>49</u>
<b>BAL &amp; Tracheal culture</b>					
<b>Likely pathogen</b>	<b>n</b>	<b>N</b>	<b>Likely contaminant</b>	<b>n</b>	<b>N</b>
<i>Klebsiella spp.</i>	17	14	<i>Candida spp</i>	21	15
<i>Escherichia coli</i>	7	5	<i>Enterococcus spp</i>	2	2
<i>Pseudomonas spp.</i>	5	4	Yeast	2	2
<i>Enterobacter spp.</i>	4	3	Upper respiratory tract flora	1	1
MRSA	4	2	<i>Streptococcus anginosus</i>	1	1
<i>Serratia marcesens</i>	3	2		<u>27</u>	<u>21</u>
<i>Staphylococcus aureus</i>	3	3			

## Co-infection in COVID-19

<i>Pluralibacter gergoviae</i>	2	1
<i>Proteus mirabilis</i>	2	2
<i>Citrobacter koseri</i>	2	2
<i>Raoultella sp.</i>	1	1
<i>Morganella morganii</i>	1	1
<i>Stenotrophomonas maltophilia</i>	1	1
<i>Haemophilus influenzae</i>	1	1
	<hr/>	<hr/>
	53	42

### Tracheal culture

Likely pathogen	n	N	Likely contaminant	n	N
<i>Serratia marcesens</i>	10	5	<i>Candida spp</i>	10	6
<i>Enterobacter spp.</i>	7	3	Yeast	6	4
<i>Escherichia coli</i>	6	2	Mixed growth of Coliform & Candida	4	2
<i>Klebsiella spp.</i>	4	3	Respiratory commensals	2	1
<i>Raoultella sp.</i>	4	1	<i>Corynebacterium sp</i>	1	1
<i>Pseudomonas spp.</i>	3	2		<hr/>	<hr/>
<i>Proteus mirabilis</i>	2	2		23	14
<i>Staphylococcus aureus</i>	2	2			
<i>Haemophilus influenzae</i>	2	1			
<i>Aspergillus fumigatus</i>	2	1			
<i>Citrobacter koseri</i>	1	1			
<i>Acinetobacter baumannii</i>	1	1			
	<hr/>	<hr/>			
	44	24			

### Sputum culture

Likely pathogen	n	N	Likely contaminant	n	N
<i>Pseudomonas spp.</i>	19	11	<i>Candida spp</i>	13	10
<i>Stenotrophomonas maltophilia</i>	7	3	<i>Enterococcus sp</i>	2	2
<i>Escherichia coli</i>	6	5	Respiratory commensals	41	32

## Co-infection in COVID-19

<i>Klebsiella spp.</i>	8	6	56	44
<i>Citrobacter koseri</i>	6	5		
<i>Enterobacter spp.</i>	6	6		
<i>Staphylococcus aureus</i>	7	6		
<i>Proteus mirabilis</i>	2	2		
<i>Serratia marcesens</i>	2	2		
<i>Burkholderia multivorans</i>	2	1		
<i>Haemophilus influenzae</i>	2	1		
<i>Pluralibacter gergoviae</i>	1	1		
<i>Delftia acidovorans</i>	1	1		
<i>Yersinia enterocolitica</i>	1	1		
<i>Acinetobacter baumannii</i>	1	1		
	<u>71</u>	<u>52</u>		

### Legend:

**n**= Number of times an organism was cultured from a test sample

**N**= Number of patients from whom the organism was cultured in that test sample

Co-infection in COVID-19

### Online Resource 5

	<b>Co-infection rate within 48 hours (1000 person-days) (95% CI)</b>
Overall	28.2 (16.7-47.7)
Excluding Nottingham University Hospitals	32.0 (17.7-57.8)

### Online Resource 6

Type of tests	On admission		After admission (within 48 hours)		Overall	
	n	N	n	N	n	N
Blood culture	223	174	89	46	312	220
BAL PCR/ culture, sputum culture, tracheal culture	18	15	34	31	52	46
Urinary pneumococcal antigen	25	25	55	51	80	76
Urinary legionella antigen	36	34	55	54	91	88
Respiratory viral PCR	119	106	32	22	151	128

**Legend:**

**n**= Number of tests done

**N**= Number of patients who had the test

## Online Resource 7

	AMR	No AMR	Unknown	Total	Resistance n (%)
<i>Klebsiella spp.</i>	18	3	2	23	Amoxicillin, 16 (88.9); Co-amoxiclav, 9 (50); Cefuroxime, 7 (38.9); Piperacillin/Taz, 5 (27.8); Meropenem, 1 (5.6)
<i>Escherichia coli</i>	11	2	0	20	Amoxicillin, 8 (72.7); Co-amoxiclav, 5 (45.5); Meropenem, 1 (9.1); Ertapenem, 1 (9.1)
<i>Enterobacter spp.</i>	7	2	0	9	Amoxicillin, 6 (85.7); Co-amoxiclav, 6 (85.7); Cefuroxime, 2 (28.6); Cefadroxil, 1 (14.3); Ceftazidime, 1 (14.3); Meropenem, 1 (14.3); Gentamicin, 1 (14.3)
<i>Pseudomonas spp.</i>	7	4	2	13	Ciprofloxacin, 2 (28.6); Ceftazidime, 2 (28.6); Piperacillin/Taz, 5 (71.4); Meropenem, 3 (42.9); Gentamicin, 1 (14.3); Amikacin, 1(14.3); Ticarcillin/ clavulanate, 1 (14.3)
<i>Serratia marcescens</i>	7	0	0	7	Amoxicillin, 1 (100); Co-amoxiclav, 6 (85.7); Cefuroxime, 1 (14.3); Piperacillin/Taz, 1 (14.3)
<i>Citrobacter koseri</i>	5	3	1	9	Amoxicillin, 5 (100); Co-amoxiclav, 1 (20); Piperacillin/Taz, 1(20); Meropenem, 1 (20)
<i>Staphylococcus aureus</i>	4	7	0	11	Flucloxacillin, 1 (25); Doxycycline, 2 (50); Clarithromycin, 3 (75); Clindamycin, 1(25)
<i>Haemophilus influenzae</i>	3	0	1	4	Amoxicillin, 3 (100); Co-amoxiclav, 3 (100); Cefuroxime, 2 (66.7); Doxycycline, 1 (33.3)
<i>Acinetobacter baumannii</i>	1	1	0	2	Ceftazidime, 1 (100)
<i>Burkholderia multivorans</i>	1	0	0	1	Gentamicin, 1 (100); Meropenem, 1 (100); Ceftolozane/Tazobactam, 1 (100)
<i>Enterococcus spp.</i>	1	2	5	8	Amoxicillin, 1 (100); Gentamicin, 1 (100)
<i>Morganella morganii</i>	1	0	0	1	Amoxicillin, 1 (100); Co-amoxiclav, 1 (100); Cefuroxime, 1 (100); Piperacillin/Taz, 1 (100)
<i>Raoultella sp.</i>	1	0	0	1	Amoxicillin, 1 (100); Piperacillin/Taz, 1 (100)
<i>Yersinia enterocolitica</i>	1	0	0	1	Amoxicillin, 1 (100); Co-amoxiclav, 1 (100)
<b>Total</b>	<b>68</b>	<b>24</b>	<b>11</b>	<b>110</b>	

## Legend

- AMR is defined as resistance reported to one or more antimicrobial agents tested. Information in this table is based on the antimicrobial patterns released by individual sites for clinicians, other resistance may have been present but not reported
- Piperacillin/Taz= Piperacillin/Tazobactam
- Co-pathogens breakdown by species
  - *Klebsiella spp.*: *Klebsiella pneumoniae*(9), *Klebsiella aerogenes* (8), *Klebsiella variicola* (1)
  - *Enterobacter spp.*: *Enterobacter cloacae* (4), *Enterobacter cloacae complex* (1), *Enterobacter aerogenes* (1)
  - *Pseudomonas spp.*: *Pseudomonas sp* (1), *Pseudomonas aeruginosa* (5)

## Co-infection in COVID-19

## References

1. McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung. *Nature reviews Microbiology*. 2014;12(4):252-62. Epub 2014/03/05. doi: 10.1038/nrmicro3231. PubMed PMID: 24590244.
2. WHO WHO. WHO Covid-19 Dashboard 2020 [02/06/20]. Available from: [https://covid19.who.int/?gclid=CjwKCAjw8df2BRA3EiwAvfZWajWnmCWZBUjdJZGVdH4hGENu8origQTHDsIst5u\\_gYXoQcl8sS\\_ZxoClxEQAvD\\_BwE](https://covid19.who.int/?gclid=CjwKCAjw8df2BRA3EiwAvfZWajWnmCWZBUjdJZGVdH4hGENu8origQTHDsIst5u_gYXoQcl8sS_ZxoClxEQAvD_BwE).
3. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *The New England journal of medicine*. 2020. Epub 2020/02/29. doi: 10.1056/NEJMoa2002032. PubMed PMID: 32109013; PubMed Central PMCID: PMCPCMC7092819.
4. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054-62. Epub 2020/03/15. doi: 10.1016/s0140-6736(20)30566-3. PubMed PMID: 32171076.
5. Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. *Journal of Allergy and Clinical Immunology*. 2020;146(1):128-36.e4. doi: 10.1016/j.jaci.2020.05.008.
6. ISARIC ISARaELC. Clinical Data Report. 2020.
7. Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, et al. C-reactive protein correlates with CT findings and predicts severe COVID-19 early. *Journal of medical virology*. n/a(n/a). doi: 10.1002/jmv.25871.
8. National Institute for Health and Care Excellence N. COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital: NICE; 2020 [cited 2020 June 2020]. Available from: <https://www.nice.org.uk/guidance/ng173/chapter/3-Initial-approach-to-antibiotic-treatment-choices>.
9. Leonas G, Bekeris, Joseph A, Tworek, Molly K, Walsh, Paul N, Valenstein. Trends in Blood Culture Contamination: A College of American Pathologists Q-Tracks Study of 356 Institutions. *Archives of Pathology & Laboratory Medicine*. 2005;129(10):1222-5. doi: 10.1043/1543-2165(2005)129[1222:Tibcca]2.0.Co;2. PubMed PMID: 16196507.
10. Hall KK, Lyman JA. Updated Review of Blood Culture Contamination. *Clinical microbiology reviews*. 2006;19(4):788. doi: 10.1128/CMR.00062-05.
11. Freeman JT, Chen LF, Sexton DJ, Anderson DJ. Blood culture contamination with Enterococci and skin organisms: Implications for surveillance definitions of primary bloodstream infections. *American Journal of Infection Control*. 2011;39(5):436-8. doi: 10.1016/j.ajic.2010.07.014.
12. Gajdács M, Dóczy I, Ábrók M, Lázár A, Burián K. Epidemiology of candiduria and Candida urinary tract infections in inpatients and outpatients: results from a 10-year retrospective survey. *Central European journal of urology*. 2019;72(2):209-14. Epub 2019/09/05. doi: 10.5173/cej.2019.1909. PubMed PMID: 31482032; PubMed Central PMCID: PMCPCMC6715075.
13. Pendleton KM, Huffnagle GB, Dickson RP. The significance of Candida in the human respiratory tract: our evolving understanding. *Pathogens and disease*. 2017;75(3). Epub 2017/04/20. doi: 10.1093/femspd/ftx029. PubMed PMID: 28423168; PubMed Central PMCID: PMCPCMC6433300.
14. Public Health England P. UK SMI B 57 issue 3.5 (May 2019): investigation of bronchoalveolar lavage, sputum and associated specimens May 2019 02/06/2020; (issue 3.5). Available from: <https://www.gov.uk/government/publications/smi-b-57-investigation-of-bronchoalveolar-lavage-sputum-and-associated-specimens>.
15. Lin E, Bhusal Y, Horwitz D, Shelburne SA, 3rd, Trautner BW. Overtreatment of enterococcal bacteriuria. *Arch Intern Med*. 2012;172(1):33-8. Epub 2012/01/11. doi: 10.1001/archinternmed.2011.565. PubMed PMID: 22232145.

## Co-infection in COVID-19

16. British Society of Thoracic Imaging B. Covid-19 BSTI reporting templates and codes 2020 [updated 22/05/2020/06/2020]. Available from: <https://www.bsti.org.uk/covid-19-resources/covid-19-bsti-reporting-templates/>.
17. Intensive Care National Audit and Research Centre I. Online reports 2020 [June 2020]. Available from: <https://onlinereports.icnarc.org/Home>.
18. Rice TW, Rubinson L, Uyeki TM, Vaughn FL, John BB, Miller RR, 3rd, et al. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. *Critical care medicine*. 2012;40(5):1487-98. Epub 2012/04/19. doi: 10.1097/CCM.0b013e3182416f23. PubMed PMID: 22511131; PubMed Central PMCID: PMCPMC3653183.
19. Arabi YM, Al-Omari A, Mandourah Y, Al-Hameed F, Sindi AA, Alraddadi B, et al. Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter Retrospective Cohort Study. *Critical care medicine*. 2017;45(10):1683-95. Epub 2017/08/09. doi: 10.1097/ccm.0000000000002621. PubMed PMID: 28787295.
20. Jang TN, Yeh DY, Shen SH, Huang CH, Jiang JS, Kao SJ. Severe acute respiratory syndrome in Taiwan: analysis of epidemiological characteristics in 29 cases. *The Journal of infection*. 2004;48(1):23-31. Epub 2003/12/12. doi: 10.1016/j.jinf.2003.09.004. PubMed PMID: 14667789; PubMed Central PMCID: PMCPMC7127319.
21. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. *Journal of Infection*. doi: 10.1016/j.jinf.2020.05.046.
22. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. *Clinical Microbiology and Infection*. 2020. doi: <https://doi.org/10.1016/j.cmi.2020.07.016>.
23. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020. Epub 2020/05/03. doi: 10.1093/cid/ciaa530. PubMed PMID: 32358954; PubMed Central PMCID: PMCPMC7197596.
24. Adler H, Ball R, Fisher M, Mortimer K, Vardhan MS. Low rate of bacterial co-infection in patients with COVID-19. *The Lancet Microbe*. 2020;1(2):e62. doi: 10.1016/S2666-5247(20)30036-7.
25. Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. *Clinical Microbiology and Infection*. 2020. doi: <https://doi.org/10.1016/j.cmi.2020.06.025>.
26. Youngs J, Wyncoll D, Hopkins P, Arnold A, Ball J, Bicanic T. Improving antibiotic stewardship in COVID-19: Bacterial co-infection is less common than with influenza. *Journal of Infection*. 2020. doi: <https://doi.org/10.1016/j.jinf.2020.06.056>.
27. Crotty MP, Akins RL, Nguyen AT, Slika R, Rahmzadeh K, Wilson MH, et al. Investigation of subsequent and co-infections associated with SARS-CoV-2 (COVID-19) in hospitalized patients. *medRxiv*. 2020:2020.05.29.20117176. doi: 10.1101/2020.05.29.20117176.
28. Kreitmann L, Monard C, Dauwalder O, Simon M, Argaud L. Early bacterial co-infection in ARDS related to COVID-19. *Intensive care medicine*. 2020. doi: 10.1007/s00134-020-06165-5.
29. Contou D, Claudinon A, Pajot O, Micaelo M, Longuet Flandre P, Dubert M, et al. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. *Ann Intensive Care*. 2020;10(1):119. Epub 2020/09/08. doi: 10.1186/s13613-020-00736-x. PubMed PMID: 32894364; PubMed Central PMCID: PMCPMC7475952.
30. Vincent J-L. Nosocomial infections in adult intensive-care units. *The Lancet*. 2003;361(9374):2068-77. doi: [https://doi.org/10.1016/S0140-6736\(03\)13644-6](https://doi.org/10.1016/S0140-6736(03)13644-6).
31. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. *Jama*. 2009;302(21):2323-9. Epub 2009/12/03. doi: 10.1001/jama.2009.1754. PubMed PMID: 19952319.

## Co-infection in COVID-19

32. Kalanuria AA, Ziai W, Mirski M. Erratum to: Ventilator-associated pneumonia in the ICU. *Critical care (London, England)*. 2016;20:29-. doi: 10.1186/s13054-016-1206-8. PubMed PMID: 26821590.
33. Nori P, Cowman K, Chen V, Bartash R, Szymczak W, Madaline T, et al. Bacterial and Fungal Co-Infections in COVID-19 Patients Hospitalized During the New York City Pandemic Surge. *Infection Control & Hospital Epidemiology*. 2020:1-13. Epub 2020/07/24. doi: 10.1017/ice.2020.368.
34. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2010;51 Suppl 1:S81-7. Epub 2010/07/06. doi: 10.1086/653053. PubMed PMID: 20597676.
35. Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. Incidence of co-infections and superinfections in hospitalised patients with COVID-19: a retrospective cohort study. *Clinical Microbiology and Infection*. doi: 10.1016/j.cmi.2020.07.041.
36. Dhesi Z, Enne VI, Brealey D, Livermore DM, High J, Russell C, et al. Organisms causing secondary pneumonias in COVID-19 patients at 5 UK ICUs as detected with the FilmArray test. *medRxiv*. 2020:2020.06.22.20131573. doi: 10.1101/2020.06.22.20131573.
37. Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens. *Jama*. 2020. Epub 2020/04/16. doi: 10.1001/jama.2020.6266. PubMed PMID: 32293646.
38. Public Health England P. PHE National Influenza Report - Week 32 report. Report. 2020 06/08/2020. Report No.: Week 32.
39. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. *Jama*. 2003;290(19):2588-98. Epub 2003/11/20. doi: 10.1001/jama.290.19.2588. PubMed PMID: 14625336.
40. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. *American journal of respiratory and critical care medicine*. 2000;162(2 Pt 1):505-11. Epub 2000/08/10. doi: 10.1164/ajrccm.162.2.9909095. PubMed PMID: 10934078.
41. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. *New England Journal of Medicine*. 2020. doi: 10.1056/NEJMoa2021436.